留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

促进我国儿童风湿免疫性疾病的精准诊疗

马明圣 宋红梅

马明圣, 宋红梅. 促进我国儿童风湿免疫性疾病的精准诊疗[J]. 协和医学杂志, 2023, 14(2): 229-233. doi: 10.12290/xhyxzz.2023-0080
引用本文: 马明圣, 宋红梅. 促进我国儿童风湿免疫性疾病的精准诊疗[J]. 协和医学杂志, 2023, 14(2): 229-233. doi: 10.12290/xhyxzz.2023-0080
MA Mingsheng, SONG Hongmei. Acceleration of Precision Medicine in Pediatric Rheumatic and Immunologic Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 229-233. doi: 10.12290/xhyxzz.2023-0080
Citation: MA Mingsheng, SONG Hongmei. Acceleration of Precision Medicine in Pediatric Rheumatic and Immunologic Diseases[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(2): 229-233. doi: 10.12290/xhyxzz.2023-0080

促进我国儿童风湿免疫性疾病的精准诊疗

doi: 10.12290/xhyxzz.2023-0080
基金项目: 

国家重点研发计划 2021YFC2702001

中国医学科学院医学与健康科技创新工程 2021-I2M-C & T-B-008

中央高水平医院临床科研专项 2022-PUMCH-B-079

详细信息
    通讯作者:

    宋红梅, E-mail:songhm1021@126.com

  • 中图分类号: R593.2

Acceleration of Precision Medicine in Pediatric Rheumatic and Immunologic Diseases

Funds: 

National Key Research and Development Program of China 2021YFC2702001

CAMS Innovation Fund for Medical Sciences 2021-I2M-C & T-B-008

National High Level Hospital Clinical Research Funding 2022-PUMCH-B-079

More Information
  • 摘要: 儿童风湿免疫性疾病涉及复杂的遗传和环境因素。目前尚无经过验证的可预测治疗应答的生物学标志物,治疗主要依据症状、治疗指南、医生经验和药物可及性。精准诊疗在我国儿童风湿免疫性疾病中的应用尚处于起步阶段,本文将以幼年特发性关节炎、儿童系统性红斑狼疮为例,探讨精准诊疗的最新进展,以期为构建我国儿童风湿免疫性疾病的精准诊疗体系提供参考,提高患儿的生活质量。
    作者贡献:马明圣负责资料收集和论文撰写;宋红梅负责论文修订并审阅定稿。
    利益冲突:所有作者均声明不存在利益冲突
  • [1] Stoustrup P, Resnick CM, Abramowicz S, et al. Manage-ment of Orofacial Manifestations of Juvenile Idiopathic Arthritis: Interdisciplinary Consensus-Based Recommendations[J]. Arthritis Rheumatol, 2023, 75: 4-14. doi:  10.1002/art.42338
    [2] Malattia C, Tolend M, Mazzoni M, et al. Current status of MR imaging of juvenile idiopathic arthritis[J]. Best Pract Res Clin Rheumatol, 2020, 34: 101629. doi:  10.1016/j.berh.2020.101629
    [3] Combier A, Frantz C, Wipff J, et al. Risk stratification using anti-citrullinated peptide antibodies (ACPA) in polyarticular subtypes of juvenile idiopathic arthritis in adulthood[J]. Joint Bone Spine, 2022, 90: 105501.
    [4] Hersh AO, Prahalad S. Immunogenetics of juvenile idiopa-thic arthritis: A comprehensive review[J]. J Autoimmun, 2015, 64: 113-124. doi:  10.1016/j.jaut.2015.08.002
    [5] Nziza N, Jeziorski E, Delpont M, et al. Synovial-Fluid miRNA Signature for Diagnosis of Juvenile Idiopathic Arthritis[J]. Cells, 2019, 8: 1521. doi:  10.3390/cells8121521
    [6] Brown RA, Henderlight M, Do T, et al. Neutrophils From Children With Systemic Juvenile Idiopathic Arthritis Exhibit Persistent Proinflammatory Activation Despite Long-Standing Clinically Inactive Disease[J]. Front Immunol, 2018, 9: 2995. doi:  10.3389/fimmu.2018.02995
    [7] Cimaz R, Maioli G, Calabrese G. Current and emerging biologics for the treatment of juvenile idiopathic arthritis[J]. Expert Opin Biol Ther, 2020, 20: 725-740. doi:  10.1080/14712598.2020.1733524
    [8] Jing W, Zhang X, Sun W, et al. CRISPR/CAS9-Mediated Genome Editing of miRNA-155 Inhibits Proinflammatory Cytokine Production by RAW264.7 Cells[J]. Biomed Res Int, 2015, 2015: 326042.
    [9] Fattal E, Fay F. Nanomedicine-based delivery strategies for nucleic acid gene inhibitors in inflammatory diseases[J]. Adv Drug Deliv Rev, 2021, 175: 113809. doi:  10.1016/j.addr.2021.05.019
    [10] Verweyen EL, Schulert GS. Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)[J]. Rheumatology (Oxford), 2022, 61: 926-935. doi:  10.1093/rheumatology/keab673
    [11] Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J]. Arthritis Rheum, 1997, 40: 1725.
    [12] Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus[J]. Arthritis Rheum, 2012, 64: 2677-2686. doi:  10.1002/art.34473
    [13] Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythemato-sus[J]. Arthritis Rheumatol, 2019, 71: 1400-1412. doi:  10.1002/art.40930
    [14] Ma M, Hui-Yuen JS, Cerise JE, et al. Validation of the 2019 European League Against Rheumatism/American College of Rheumatology Criteria Compared to the 1997 American College of Rheumatology Criteria and the 2012 Systemic Lupus International Collaborating Clinics Criteria in Pediatric Systemic Lupus Erythematosus[J]. Arthritis Care Res (Hoboken), 2020, 72: 1597-1601. doi:  10.1002/acr.24057
    [15] Demirkaya E, Sahin S, Romano M, et al. New Horizons in the Genetic Etiology of Systemic Lupus Erythematosus and Lupus-Like Disease: Monogenic Lupus and Beyond[J]. J Clin Med, 2020, 9: 712. doi:  10.3390/jcm9030712
    [16] Batu ED, Kosukcu C, Taskiran E, et al. Whole Exome Sequencing in Early-onset Systemic Lupus Erythematosus[J]. J Rheumatol, 2018, 45: 1671-1679. doi:  10.3899/jrheum.171358
    [17] He Y, Gallman AE, Xie C, et al. P2RY8 variants in lupus patients uncover a role for the receptor in immunological tolerance[J]. J Exp Med, 2022, 219: e20211004. doi:  10.1084/jem.20211004
    [18] Bentham J, Morris DL, Graham DSC, et al. Genetic association analyses implicate aberrant regulation of innate and adaptive immunity genes in the pathogenesis of systemic lupus erythematosus[J]. Nat Genet, 2015, 47: 1457-1464. doi:  10.1038/ng.3434
    [19] Julia A, Lopez-Longo FJ, Perez Venegas JJ, et al. Genome-wide association study meta-analysis identifies five new loci for systemic lupus erythematosus[J]. Arthritis Res Ther, 2018, 20: 100. doi:  10.1186/s13075-018-1604-1
    [20] Martinez-Bueno M, Alarcon-Riquelme ME. Exploring Impact of Rare Variation in Systemic Lupus Erythematosus by a Genome Wide Imputation Approach[J]. Front Immunol, 2019, 10: 258. doi:  10.3389/fimmu.2019.00258
    [21] Omarjee O, Picard C, Frachette C, et al. Monogenic lupus: Dissecting heterogeneity[J]. Autoimmun Rev, 2019, 18: 102361. doi:  10.1016/j.autrev.2019.102361
    [22] Brown GJ, Canete PF, Wang H, et al. TLR7 gain-of-function genetic variation causes human lupus[J]. Nature, 2022, 605: 349-356. doi:  10.1038/s41586-022-04642-z
    [23] Xu L, Zhao J, Sun Q, et al. Loss-of-function variants in SAT1 cause X-linked childhood-onset systemic lupus erythematosus[J]. Ann Rheum Dis, 2022, 81: 1712-1721. doi:  10.1136/annrheumdis-2022-eular.4424
    [24] Wang TY, Wang YF, Zhang Y, et al. Identification of Regulatory Modules That Stratify Lupus Disease Mechanism through Integrating Multi-Omics Data[J]. Mol Ther Nucleic Acids, 2020, 19: 318-329. doi:  10.1016/j.omtn.2019.11.019
    [25] Der E, Suryawanshi H, Morozov P, et al. Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways[J]. Nat Immunol, 2019, 20: 915-927. doi:  10.1038/s41590-019-0386-1
    [26] Arazi A, Rao DA, Berthier CC, et al. The immune cell landscape in kidneys of patients with lupus nephritis[J]. Nat Immunol, 2019, 20: 902-914. doi:  10.1038/s41590-019-0398-x
    [27] Nehar-Belaid D, Hong S, Marches R, et al. Mapping systemic lupus erythematosus heterogeneity at the single-cell level[J]. Nat Immunol, 2020, 21: 1094-1106. doi:  10.1038/s41590-020-0743-0
    [28] van Vollenhoven RF, Petri MA, Cervera R, et al. Belimu-mab in the treatment of systemic lupus erythematosus: high disease activity predictors of response[J]. Ann Rheum Dis, 2012, 71: 1343-1349. doi:  10.1136/annrheumdis-2011-200937
    [29] Brunner HI, Abud-Mendoza C, Viola DO, et al. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial[J]. Ann Rheum Dis, 2020, 79: 1340-1348. doi:  10.1136/annrheumdis-2020-217101
    [30] Furie R, Nicholls K, Cheng TT, et al. Efficacy and safety of abatacept in lupus nephritis: a twelve-month, randomized, double-blind study[J]. Arthritis Rheumatol, 2014, 66: 379-389.
    [31] Group AT. Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study[J]. Arthritis Rheumatol, 2014, 66: 3096-3104. doi:  10.1002/art.38790
    [32] Goldberg A, Geppert T, Schiopu E, et al. Dose-escalation of human anti-interferon-alpha receptor monoclonal antibody MEDI-546 in subjects with systemic sclerosis: a phase 1, multicenter, open label study[J]. Arthritis Res Ther, 2014, 16: R57. doi:  10.1186/ar4492
    [33] Kalunian KC, Merrill JT, Maciuca R, et al. A Phase Ⅱ study of the efficacy and safety of rontalizumab (rhuMAb interferon-alpha) in patients with systemic lupus erythematosus (ROSE)[J]. Ann Rheum Dis, 2016, 75: 196-202. doi:  10.1136/annrheumdis-2014-206090
  • 加载中
计量
  • 文章访问数:  3332
  • HTML全文浏览量:  43
  • PDF下载量:  181
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-02-13
  • 录用日期:  2023-03-07
  • 网络出版日期:  2023-03-16
  • 刊出日期:  2023-03-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!